Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases Aclaris Therapeutics Inc. (ACRS) is a biopharmaceutical company specializing in developing… BioTech Health XNovember 20, 2024 0 Shares 0 0 0 0 0 0 0
Pulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations BioTech Health XNovember 17, 2024
UroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch BioTech Health XNovember 17, 2024
ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study BioTech Health XNovember 14, 2024
Biotech NewsAclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases BioTech Health XNovember 20, 2024
Biotech NewsPulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations BioTech Health XNovember 17, 2024
Biotech NewsUroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch BioTech Health XNovember 17, 2024
Biotech NewsABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study BioTech Health XNovember 14, 2024
Aclaris (ACRS) Advances Groundbreaking Therapies for Autoimmune Diseases BioTech Health XNovember 20, 2024 Aclaris Therapeutics Inc. (ACRS) is a biopharmaceutical company specializing in developing innovative therapies for immuno-inflammatory diseases. With a… Read More 0 Shares 0 0 0 0 0 0 0
Pulmonx (LUNG) Reports $68.7M Revenue with 28% Growth and COPD Innovations BioTech Health XNovember 17, 2024 Pulmonx Corporation (LUNG), a leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), reported a record… Read More 0 Shares 0 0 0 0 0 0 0
UroGen (URGN) Posts $25.2M Q3 Revenue, Targets $5B Market with UGN-102 Launch BioTech Health XNovember 17, 2024 UroGen Pharma Ltd. (URGN), a biotechnology company revolutionizing cancer care, announced Q3 2024 revenue of $25.2 million, a… Read More 0 Shares 0 0 0 0 0 0 0
ABBV-RGX-314 Gene Therapy Reduces nAMD Injections in Bilateral Study BioTech Health XNovember 14, 2024 In a major advancement for treating neovascular age-related macular degeneration (nAMD), the investigational gene therapy ABBV-RGX-314 of Regenxbio… Read More 0 Shares 0 0 0 0 0 0 0
Rigel (RIGL)’s Q3 2024 Revenue Hits $55.3M BioTech Health XNovember 12, 2024 Rigel Pharmaceuticals, Inc. (RIGL), a biotech leader in hematologic disorders and oncology, reported strong Q3 2024 financial growth… Read More 0 Shares 0 0 0 0 0 0 0
Lakeside Holding (LSH) Acquires Hupan Pharmaceutical to Enter China’s Medical Logistics Market BioTech Health XNovember 11, 2024 Lakeside Holding Limited (LSH), a U.S.-based leader in cross-border supply chain solutions, has officially expanded into the medical… Read More 0 Shares 0 0 0 0 0 0 0
Autolus (AUTL) Reports Obe-cel Launch Progress and Strong Cash Position in Q2 2024 BioTech Health XNovember 10, 2024 Autolus Therapeutics plc (AUTL), a leader in T-cell therapies, announced its Q2 2024 financial results and business updates.… Read More 0 Shares 0 0 0 0 0 0 0
FDA Clears CEL-SCI’s Multikine Study for Head and Neck Cancer BioTech Health XNovember 8, 2024 CEL-SCI Corporation (CVM), a leader in immunotherapy, announced FDA approval of its patient selection strategy for the upcoming… Read More 0 Shares 0 0 0 0 0 0 0
Aethlon (AEMD) Reports Q1 2024 Results and Advances Cancer and Virus Treatment Trials BioTech Health XNovember 7, 2024 Aethlon Medical, Inc. (AEMD), a pioneering company in cancer and infectious disease therapies, has reported its fiscal Q1… Read More 0 Shares 0 0 0 0 0 0 0
Treace Medical (TMCI) Reports 11% Revenue Growth in Q3 2024 BioTech Health XNovember 6, 2024 Treace Medical Concepts, Inc. (TMCI), a leading innovator in the medical technology space focused on bunion treatment, announced… Read More 0 Shares 0 0 0 0 0 0 0
Taysha Gene (TSHA) Reports Strong Q2 2024 Results and Advances TSHA-102 Trials BioTech Health XNovember 5, 2024 Taysha Gene Therapies, Inc. (TSHA), a leader in developing AAV-based gene therapies for severe central nervous system diseases,… Read More 0 Shares 0 0 0 0 0 0 0
CEL-SCI’s Multikine Immunotherapy Boosts 5-Year Survival Rate in Head and Neck Cancer BioTech Health XSeptember 16, 2024 CEL-SCI Corporation (NYSE American: CVM) has announced new breakthrough data from its Phase 3 trial of Multikine®, an… Read More 0 Shares 0 0 0 0 0 0 0
Novartis Pioneers RNA Therapeutics with Borealis Biosciences for Kidney Diseases BioTech Health XAugust 22, 2024 Introduction In a groundbreaking move for the biotech industry, Novartis has partnered with Versant Ventures to establish Borealis… Read More 0 Shares 0 0 0 0 0 0 0
Genentech’s Strategic Pivot: The Closure of Its Cancer Immunology Unit BioTech Health XAugust 22, 2024 Introduction In a significant and somewhat unexpected move within the biotech industry, Genentech, a subsidiary of Roche, has… Read More 0 Shares 0 0 0 0 0 0 0
Breakthrough in Alzheimer’s Treatment: Biogen and Eisai’s Leqembi Wins UK Approval BioTech Health XAugust 22, 2024 Introduction The landscape of Alzheimer’s disease treatment has undergone a monumental shift with the UK’s Medicines and Healthcare… Read More 0 Shares 0 0 0 0 0 0 0
Vera Therapeutics’ Atacicept Shows Promising Results in Phase 2b ORIGIN Trial for IgA Nephropathy BioTech Health XMay 25, 2024 Vera Therapeutics has announced positive results from their Phase 2b ORIGIN clinical trial for atacicept, a novel investigational… Read More 0 Shares 0 0 0 0 0 0 0
Ozempic Shows Lower Risk of Kidney and Heart Complications in Diabetic Patients BioTech Health XMay 24, 2024 In a groundbreaking development, Novo Nordisk’s Ozempic (semaglutide) has demonstrated significant benefits in reducing the risk of kidney… Read More 0 Shares 0 0 0 0 0 0 0
Eli Lilly Announces Historic $5.3 Billion Investment to Expand Indiana Manufacturing for Diabetes and Weight Loss Drugs BioTech Health XMay 24, 2024 Expansion to Create 900 Permanent Jobs and Meet Rising Demand for Mounjaro and Zepbound Eli Lilly and Company… Read More 0 Shares 0 0 0 0 0 0 0